Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00447187 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
A Phase 3 study, sponsored by Lux Biosciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 368
- Enrollment target
NCT00447187 is a Phase 3 study that was terminated before completion, run by Lux Biosciences. The registered enrollment target is 368 participants.
The verdict
NCT00447187, a Phase 3 study, was terminated before completion, sponsored by Lux Biosciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 368 participants
- Enrollment target
Study Summary
This was a pivotal trial to determine whether LX201 reduces the likelihood of a graft rejection episode following corneal transplantation in patients at high immunological risk for rejection.
Interventions
- OTHER Placebo
- DRUG LX201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00447187
The ClinicalTrials.gov registry entry for NCT00447187 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 368 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lux Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00447187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00447187 about?
NCT00447187 is a clinical study titled "Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk". This was a pivotal trial to determine whether LX201 reduces the likelihood of a graft rejection episode following corneal transplantation in patients at high immunological risk for rejection.
What is the current status of trial NCT00447187?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 368 participants. The study started on 2007-04. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00447187?
The interventions under investigation include: Placebo (OTHER), LX201 (DRUG).
Who is sponsoring clinical trial NCT00447187?
This trial is sponsored by Lux Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.